ProNano, the micro-volume spectrophotometer is designed for quick and accurate quantification of protein analysis. Focusing on BCA, Bradford and Pierce 660 assay. ProNano has light source with three wavelengths for most of the quantification requirements of protein.

Unlike traditional methods, ProNano needs less sample size, less reacting time, and provides the same performance. Only 2ul samples are needed to be measured, and only 10 minutes reacting time is required, which is much less than traditional 30 mins to 2 hours. The linearity reaches Rsquare > 0.99 for every assay, and reproducibility is stable.

Like MaestroNano spectrophotometer, ProNano needs no calibration, and can be operated by embedded system. Also, the saved data can be accessed by USB port to PC.

Price: 4563 € 

Download ProNano brochure

Download ProNano datasheet

Download ProNano presenatation

Order ProNano right now !

Researchers from the Hebrew University of Jerusalem and the Weizmann Institute of Science have developed a technique to cause apoptosis, or programmed cell death, that could lead to new approaches to treating cancer. 

Apoptosis is an essential defense mechanism against the spread of abnormal cells such as cancer. It is a complex process that occurs through networks of proteins that interact with each other. Cancer cells usually avoid this process due to mutations in the genes that encode the relevant proteins. The result is that the cancer cells survive and take over while healthy cells die.

The research, by graduate student Chen Hener-Katz at the Hebrew University, involved collaboration between Prof. Assaf Friedler of the Hebrew University's Institute of Chemistry and Prof. Atan Gross of the Weizmann Institute's Department of Biological Regulation. It was published in the Journal of Biological Chemistry under the title ''Molecular Basis of the Interaction between Proapoptotic Truncated BID (tBID) Protein and Mitochondrial Carrier Homologue 2 (MTCH2) Protein.''

The study examined the interaction between two important proteins involved in cell death: mitochondrial carrier homologue 2 (MTCH2), which was discovered in the lab of Prof. Gross, and truncated BID (tBID), which are both involved in the apoptotic process. The researchers found the regions in the two proteins that are responsible for binding to each other, a critical step in initiating apoptosis. Following their discovery, the researchers developed short synthetic protein fragments, or peptides, that mimicked the areas on the proteins that bind to each other, and by doing so inhibited this binding. In lab experiments conducted on cell cultures, this resulted in the death of cancer cells of human origin.

''These protein segments could be the basis of future anti-cancer therapies in cases where the mechanism of natural cell death is not working properly,'' said Prof. Friedler. ''We have just begun to uncover the hidden potential in the interaction between these proteins. This is an important potential target for the development of anticancer drugs that will stimulate apoptosis by interfering with its regulation. ''

Prof. Friedler is the head of the school of chemistry at the Hebrew University. His major research interests are using peptides to study protein-protein interactions in health and disease, and developing peptides as drug leads that modulate these interactions, specifically in relation to HIV and cancer. Prof. Friedler won the prestigious starting grant from the ERC (European Research Council) as well as the outstanding young scientist prize by the Israeli Chemical Society. His research was supported by a grant from the Israel Ministry of Health and by a starting grant from the European Research Council. 

PRODUCT DESCRIPTION:
NATtrol™ MRSA.SA Panel (NATMRSA.SAP-C) is formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. NATMRSA.SAP-C contains 5 x 0.5 mL vials of S. aureus or S. epidermidis NATtrol™ as listed in Table 1. These panels are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

INTENDED USE:
- NATtrol™ MRSA.SA Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence of S. aureus DNA. NATMRSA.SAP-C can also be used for verification of clinical assays, development of diagnostic tests and training of laboratory personnel.
- NATMRSA.SAP-C contains intact organisms and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:
- NATtrol™ inactivation was carried out on the bacterial stock used to formulate panel members. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
- The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

Catalog #: NATMRSA.SAP-C

For more information download PDF file

PRODUCT DESCRIPTION:
NATtrol™ BC.GP Panel (NATBC.GP-NNS) is formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. NATBC.GP-NNS contains 11 x 0.75 mL vials of bacterial NATtrol™ targets listed in Table 1. These panels are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

INTENDED USE:
- NATtrol™ BC.GP Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence of bacterial nucleic acids. NATBC.GP-NNS can also be used for verification of clinical assays, development of diagnostic tests and training of laboratory personnel.
- NATBC.GP-NNS contains intact organisms and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:
- NATtrol™ inactivation was carried out on the bacterial stock used to formulate panel members. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
- The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

PRECAUTIONS:
- Although NATBC.GP-NNS contains inactivated organisms, it should be handled as if potentially infectious.
- Use Universal Precautions when handling this product.
- To avoid cross-contamination, use separate pipette tips for all reagents.

Catalog #: NATBC.GP-NNS 

For more information donwload PDF file